Aim: To describe treatment patterns and outcomes for advanced/metastatic non-small-cell lung cancer (aNSCLC) treated with single-agent or combination ramucirumab (ramucirumab-based) and/or immune checkpoint inhibitor (ICI-based) therapy. Materials & methods: Retrospective study of aNSCLC patients (n = 4054) identified in the Flatiron Health database, who received at least two treatment lines including ramucirumab- and/or ICI-based regimens between December 2014 and May 2017. Results: Median overall survival (95% CI) from aNSCLC diagnosis was 29.3 (25.5–33.0) months for patients receiving sequential ramucirumab- and ICI-based therapy (n = 245), 15.1 (12.6–18.2) months for patients receiving sequences including ramucirumab- without ICI-based therapy (n = 112), and 23.1 (21.9–24.2) months for patients receiving ICI-based therapy without ramucirumab-based therapy in sequence (n = 3697). Conclusion: Results provide real-world survival estimates for aNSCLC treated with sequences including ramucirumab- and/or ICI-based therapies.

No abstract

Abs1l"act: This paper presents II lrnll5llclion log analysis of RcscaJl:bIndcx, a digital librnry for computcr scicncc rescarchcl1>. Rcscnn:bTndcx is an impol1:lll1 information resource for members of Ihis target group, and the colleclion sees significant use worldwide. Queries fmm over six months of usagc were analyzed, to dcterminc paUcms in query cOll'ilrUction and scan:h session behavior. Whcrc appropriatc, Ihcsc results arc compared to earlier studies of search behavior in two other computing digitallibrnries.

No abstract

No abstract